Please login to the form below

Not currently logged in
Email:
Password:

Amarillo Biosciences appoints Stephen Chen chair and CEO

He replaces Joseph Cummins, who will remain as the US biotech's chief operating officer

Amarillo Biosciences has selected Dr Stephen Chen, one of its directors, to take on the roles of CEO and chair.

Dr Chen takes over from Joseph Cummins, who will remain as the US biotech's president and chief operating officer.

Chen has been at Texas-based Amarillo since 1996, and has over 30 years' experience in the pharma and healthcare industry.

During this time he has held executive positions in R&D and business at several major pharma companies, including Burroughs Wellcome (now GlaxoSmithKline), Miles Pharmaceuticals (now Bayer), ICI America (now AstraZeneca), and Ciba-Geigy (now Novartis).

Since May 1992, he has been CEO of STC International, a US-based healthcare investment firm.

As CEO at Amarillo, Chen will lead operations at the company, which focus on research into the use of low-dose, oral interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough and HIV-related infections.

27th February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics